Impact of Bacterial Expression and Immune Response in the Severity of Pertussis (PERT-SEVEREII)
Sponsor: CHR - Hôpital Roger Salengo
Listed as NCT05897879, this NA trial focuses on Bordetella Pertussis, Whooping Cough and remains actively recruiting participants. Sponsored by CHR - Hôpital Roger Salengo, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Jun 2024 [monthly]
Not Yet Recruiting NA
-
Jul 2023 — Nov 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CHR - Hôpital Roger Salengo
- Centre Hospitalier Intercommunal Creteil
- Hopital Universitaire Robert-Debre
- Hospices Civils de Lyon
- Hôpital Armand Trousseau
- Hôpital Louis Mourier
- Hôpital Necker-Enfants Malades
- Hôpital Nord - APHM
- Hôpital de la Timone
- Institut Pasteur
- Nantes University Hospital
- Réseau ACTIV
- University Hospital, Bordeaux
- University Hospital, Rouen
- University Hospital, Toulouse
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Colombes, France , Créteil, France , Lille, France , Lyon, France , Marseille, France , Nantes, France , Paris, France , Rouen, France , Saint-Maur-des-Fossés, France and 1 more location